DIMAPUR, FEBRUARY 22 (MExN): Nucleomed, a Nuclear Medicine and PETCT centre of Guwahati today got clearance from Atomic Energy Regulatory Board, GOI to use Lutetium 177 PSMA & Lu-177 DOTATOC for treatment of Advance Prostate Cancer and Neuroendocrine Tumours after few months of scrutiny.
Dr Cidananda Bhuyan senior Medical oncologist, Dr Sujit Saikia senior Urologist and Dr Kamal Chetri prominent Gastroenterologist of Guwahati opined that this Beta Radiation therapy for the first time in Assam is going to be of immense help in their field of treatment.
Sending first patients for Advance Prostate Cancer therapy by Lu-177PSMA to Nucleomed, Managing Director of NE Cancer Hospital said that now all kind of Cancer Therapies or Diagnosis are available in Assam, Patients need not got to outside of the state anymore.
Dr B J Saikia, prof & Head Medical Oncology of B Borooah Cancer Institute while Congratulating Dr Kandarpa Saikia the Head of Nucleomed, said that this centre could start a new era in Molecular Imaging and Therapy in Assam and North East .
Lutetium 177 PSMA Prostate cancer is the most commonly diagnosed cancer among men in the world. Although many patients present with localised or indolent disease, there are still a significant proportion of patients that eventually progress to advanced metastatic disease, for which no curative treatment exists.
In men who fail initial therapy of curative intent (radical prostatectomy or primary radiotherapy), treatment options include androgen deprivation therapy followed by chemotherapy if the disease progresses. However, conventional chemotherapy responses are often transient, leaving many men with symptomatic metastatic cancer and few treatment options.
In such situation targeted radionuclide therapies with 177Lutetium‐PSMA is the only viable therapeutic option in men with metastatic advance prostate cancer.
Likewise 177Lutetium DOTATOC has shown better results in advanced Gastroenteropancreatic and Bronchial Neuroendocrine tumors when compared with other therapies available.
